1. Home
  2. Analysis
  3. Sulfasalazine
  4. Mavik

Sulfasalazine and Mavik drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 45 people who take Sulfasalazine and Mavik. Common interactions include limb injury among females, and dysgeusia among males.

The phase IV clinical study analyzes what interactions people who take Sulfasalazine and Mavik have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

45 people who take Sulfasalazine and Mavik together, and have interactions are studied.

What is Sulfasalazine?

Sulfasalazine has active ingredients of sulfasalazine. It is used in rheumatoid arthritis. Currently, eHealthMe is studying from 90,771 Sulfasalazine users.

What is Mavik?

Mavik has active ingredients of trandolapril. It is used in high blood pressure. Currently, eHealthMe is studying from 3,096 Mavik users.

Number of Sulfasalazine and Mavik reports submitted per year:

Sulfasalazine and Mavik drug interactions.

Common Sulfasalazine and Mavik drug interactions by gender *:

female:

  1. Limb injury
  2. Parosmia
  3. Pyrexia
  4. Sepsis
  5. Sinusitis
  6. Urinary tract infection
  7. Viral upper respiratory tract infection
  8. Cough
  9. Pain in extremity
  10. Peripheral swelling

male:

  1. Dysgeusia
  2. Thrombocytopenia
  3. Arthralgia
  4. Back injury
  5. Back pain
  6. Bicytopenia
  7. Confusional state
  8. Eczema
  9. Fall
  10. Gastric infection

Common Sulfasalazine and Mavik drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Cough
  2. Infusion related reaction
  3. Pain in extremity
  4. Stress
  5. Chest pain
  6. Contusion
  7. Paraesthesia
  8. Peripheral swelling
  9. Blood pressure fluctuation
  10. Nasopharyngitis

60+:

  1. Vomiting
  2. Dysgeusia
  3. Pain
  4. Peripheral nerve injury
  5. Streptococcal sepsis
  6. Weight increased
  7. Blood pressure fluctuation
  8. Cough
  9. Sinusitis
  10. Vein disorder

Common conditions people have *:

  1. Ankylosing Spondylitis (type of arthritis affecting the spine): 8 people, 17.78%
  2. Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Sulfasalazine and Mavik?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Sulfasalazine drug interactions:

Browse interactions between Sulfasalazine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mavik drug interactions:

Browse interactions between Mavik and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sulfasalazine and trandolapril (the active ingredients of Sulfasalazine and Mavik, respectively), and Sulfasalazine and Mavik (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Sulfasalazine and Mavik.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.